This trial is evaluating whether Branebrutinib will improve 1 primary outcome and 23 secondary outcomes in patients with Eczema, Infantile. Measurement will happen over the course of At week 16.
This trial requires 150 total participants across 5 different treatment groups
This trial involves 5 different treatments. Branebrutinib is the primary treatment being studied. Participants will be divided into 4 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
"Common treatments for dermatitis include topical steroids such as corticosteroids or tretinoin. The use of a shampoo or pomade has been shown to decrease symptoms. For more severe manifestations, systemic or oral corticosteroids may be prescribed. Another option is topical cyclosporine to prevent infection. For severe cases of dermatitis, topical tacrolimus or pimecrolimus has proven fruitful." - Anonymous Online Contributor
"Almost 1 in 6 adults has atopic dermatitis on an at least-minimal basis in the United States annually. Dermatitis affects 8.4 million adults aged 3 years and older. Dermatitis is one of the most common reasons for physician visits." - Anonymous Online Contributor
"Contact to the skin is common. There is usually some type of chemical irritant involved, and some instances can be allergic (e.g., penicillin allergy). Most dermatoses are viral, with a rare bacterial or fungal origin. Skin diseases are also very prone to secondary skin infections, and, if untreated, can lead to malignant transformation." - Anonymous Online Contributor
"Many of the signs and symptoms of dermatitis have been shown to be due to psychological factors, and only when other factors are excluded, will dermatitis be diagnosed in a patient. The lack of specific diagnostic tests does not justify indiscriminate dermatitis treatment, particularly for patients in whom the cause is psychiatric, psychosomatic, or other unknown." - Anonymous Online Contributor
"(1) It is difficult to justify the expense of dermatitis treatment in view of the minimal impact it has on most patients. (2) The value of this disease in treating, say, psoriasis is debatable, as the only people who are likely to benefit are patients with a very severe pruritic dermatitis. Even then, some people with severe psoriasis may benefit in other ways; in particular, they might benefit from reduction of inflammation by taking a calcineurin inhibitor. (3) It is important to know that psoriasis is not a curable disease, and that treatment should be tailored to the needs and expectations of the patient." - Anonymous Online Contributor
"dermatitis is a skin disease, particularly of the chronic forms, that is caused by one's immune system over-responsively reacting to harmless substances that the body should not be reacting to. dermatitis usually appears as burning, itching, and dryness, among others, in a particular area of skin, where the condition originates. The skin can also become inflamed and red and it can also become irritated if touched, a type of pain that is most common among children, and the elderly. Dermatitis causes pain and discomfort and, in the most severe or chronic forms, can cause health problems that can lead to death if not treated." - Anonymous Online Contributor
"Branebrutinib has a broad spectrum of side effects; it can cause gastrointestinal disorders (including diarrhea, abdominal pain, and nausea), skin and subcutaneous tissues irritation, headache, dizziness, vomiting, constipation and dyspnea." - Anonymous Online Contributor
"Clinical trials do not offer a reliable way to predict who will [participate in trials of new treatments, or fail to improve, after treatment in clinical practice] obtain a benefit from new treatments, but they do offer an opportunity to help determine who best needs treatment. In light of this we argue that there is an urgent need to [consider applying to clinical trials for dermatitis with caution]." - Anonymous Online Contributor
"Most dermatitis cases were secondary to [environmental factors, including cosmetics, medications, and exposures to infectious agents and chemicals as well as allergic reactions to contact with skin]. Primary causes of dermatitis that need to be taken into account while making a definitive diagnosis include skin contact infections." - Anonymous Online Contributor
"Both the safety and pharmacokinetics of branebrutinib were similar to those in the placebo/Bratu cohort. Branebrutinib is safe to use in people with relapsed or refractory multiple myeloma." - Anonymous Online Contributor
"Although the mechanism of action for branebrutinib isn't known, clinical responses are seen in patients, even subjects who have never been treated before, and branebrutinib represents an invaluable therapy for some patients with rituximab-refractory Waldenström macroglobulinemia." - Anonymous Online Contributor
"Branebrutinib is predominantly used in combination with at least one other treatment, with no clear indication for which treatment is used. In patients with ALK-positive metastatic non-small cell non-small cleaved lung cancer, the optimal combination regimen has not been established." - Anonymous Online Contributor